DNA methylation alterations in prostate cancer: from diagnosis to treatment
Translational Andrology and Urology · 2025-02 · 14 (2) · 454-462
DOI: 10.21037/tau-24-382 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Translational Andrology and Urology, 2025-02. Verfasst von Francesco Barletta und 18 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Epigenetics, particularly DNA methylation, plays a crucial role in gene activation and deactivation. Indeed, modification of this pathway has been well described as promoter of cancer development in many settings. Hypermethylation of CpG islands has also been described as a significant epigenetic alteration in prostate cancer (PCa), being associated with gene silencing and tumour progression. Key studies have shown that specific genes, such as GSTP1, APC, and RARb2, exhibit significant epigenetic alterations in PCa, with their methylation profiles showing potential utility as biomarkers in the diagnostic setting. Furthermore, comprehensive methylation analyses have identified numerous differentially methylated CpGs and relative molecular pathways associated with PCa carcinogenesis and progression, thus enhancing the understanding of its molecular underpinnings. Finally, therapies targeting DNA methylation, such as DNA methyltransferases (DNMTs) inhibitors, show potential in overcoming drug resistance in advanced PCa treatment. Consequently, dissecting epigenetic mechanisms, and in particular DNA methylation, is fundamental for understanding PCa carcinogenesis, providing valuable insights for clinical decisions and development of targeted therapies. Given the above premises, this review aims to provide an overview of the role of DNA methylation aberrations in PCa, highlighting current and future directions for exploring the epigenetic landscape to better understand the origins and progression of this disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Vita-Salute San Raffaele University, Milan, Italy.
- Department of Pathology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Center for Omics Sciences, IRCCS San Raffaele Scientific Institute-Vita-Salute San Raffaele University, Milan, Italy.
- Department of Radiology, IRCCS San Raffaele Scientific Institute-Vita-Salute San Raffaele University, Milan, Italy.
Zitieren
APA
Barletta, F., Bandini, M., Cirulli, G. O., Zaurito, P., Lucianò, R., Giannese, F., Scotti, G. M., Oneto, C., Tenace, N., Scarfò, F., Morelli, M. J., Lazarevic, D., De Cobelli, F., Ponzoni, M., Doglioni, C., Tonon, G., Gandaglia, G., Montorsi, F., & Briganti, A. (2025). DNA methylation alterations in prostate cancer: from diagnosis to treatment. Translational Andrology and Urology, 14(2), 454-462. https://doi.org/10.21037/tau-24-382
Vancouver
Barletta F, Bandini M, Cirulli GO, Zaurito P, Lucianò R, Giannese F, et al. DNA methylation alterations in prostate cancer: from diagnosis to treatment. Translational Andrology and Urology. 2025;14(2):454-462. doi:10.21037/tau-24-382
BibTeX
@article{Barletta2025,
author = {Barletta, Francesco and Bandini, Marco and Cirulli, Giuseppe Ottone and Zaurito, Paolo and Lucianò, Roberta and Giannese, Francesca and Scotti, Giulia Maria and Oneto, Caterina and Tenace, Nazario and Scarfò, Federico and Morelli, Marco J and Lazarevic, Dejan and De Cobelli, Francesco and Ponzoni, Maurilio and Doglioni, Claudio and Tonon, Giovanni and Gandaglia, Giorgio and Montorsi, Francesco and Briganti, Alberto},
title = {DNA methylation alterations in prostate cancer: from diagnosis to treatment},
journal = {Translational Andrology and Urology},
year = {2025},
volume = {14},
number = {2},
pages = {454--462},
doi = {10.21037/tau-24-382}
}
EUVIMED